China 
Africa 
Explore chapters and articles related to this topic
Pulmonary reactions to chemotherapeutic agents: the ‘chemotherapy lung’
Published in Philippe Camus, Edward C Rosenow, Drug-induced and Iatrogenic Respiratory Disease, 2010
Fabien Maldonado, Andrew H Limper
Imatinib mesylate is another tyrosine kinase inhibitor, which was specifically designed to treat chronic myelogenous leukaemia. This myeloproliferative disorder is characterized by the bcr-abl rearrangement responsible for the production of an aberrant tyrosine kinase targeted by imatinib mesylate. Rare cases of pulmonary complications presumably secondary to imatinib mesylate have been described.76,77 Interstitial pneumonitis may present early in the course of the disease, but late-onset fibrosis has also been described. This agent has also been associated with the development of cardiac insufficiency with pleural effusions and pulmonary oedema on that basis. Discontinuation of the drug should be considered in the presence of unexplained pulmonary infiltrates.
Guar gum-g-poly(N-acryloyl-L-phenyl alanine) based pH responsive smart hydrogels for in-vitro anticancer drug delivery
Published in Soft Materials, 2022
Jalababu Ramani, Madhusudhan Alle, Garima Sharma, K.V.N. Suresh Reddy, Yeongmin Park, K.S.V. Krishna Rao, Jin-Chul Kim
Chemotherapy is the most practiced method to treat cancer to date. Various chemotherapeutic agents, such as plant alkaloids, alkylating agents, antimetabolites, and tumor-specific antibiotics, are used against specific cancers.[21] At the same time, some agents, such as doxorubicin, cisplatin, and paclitaxel, are used to treat multiple cancers. However, these drugs can cause toxicities and adverse side effects to normal healthy tissues. Thus, polysaccharide-based nanoparticle-mediated stimuli-responsive delivery of chemotherapeutic drugs can be a safe and effective method to treat cancer while reducing the toxicity level in healthy cells. Imatinib mesylate (IMS), an anticancer drug, is used to treat chronic myeloid leukemia (CML), gastrointestinal stromal tumors (GISTs), and other malignancies.[22] The IMS targets cancer-specific molecules and retards the growth of the tumor cells by inhibiting the action of the tyrosine kinase enzyme. In addition, IMS also inhibits and damages the growth of nonspecific fast-dividing cells.[23]